Dahlhamer J, Lucas J, Zelaya, Carla, et al. Prevalence of chronic pain and high-impact chronic pain among adults — United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(36):1001–1006. https://doi.org/10.15585/mmwr.mm6736a2.

Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2017 National Survey on Drug Use and Health. U.S. Department of Health and Human Services.

Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol. 2008;16(5):405–16. https://doi.org/10.1037/a0013628.

Article  PubMed  PubMed Central  Google Scholar 

Dalal S, Chitneni A, Berger AA, et al. Buprenorphine for chronic pain: a safer alternative to traditional opioids. Health Psychol Res. 2021;9(1). https://doi.org/10.52965/001c.27241.

Poliwoda S, Noor N, Jenkins JS, et al. Buprenorphine and its formulations: a comprehensive review. Health Psychol Res. 2022;10(3). https://doi.org/10.52965/001c.37517.

Gress K, Charipova K, Jung JW, et al. A comprehensive review of partial opioid agonists for the treatment of chronic pain. Best Pract Res Clin Anaesthesiol. 2020;34(3):449–61. https://doi.org/10.1016/j.bpa.2020.06.003.

Article  PubMed  Google Scholar 

Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol. United States Department of Health and Human Services.

Windish DM, Catalanotti JS, Zaas A, Kisielewski M, Moriarty JP. Training in safe opioid prescribing and treatment of opioid use disorder in internal medicine residencies: a National Survey of Program Directors. J Gen Intern Med. 2022;37(11):2650–60. https://doi.org/10.1007/s11606-021-07102-y.

Article  PubMed  Google Scholar 

Hasoon J, Nguyen A, Urits I, Robinson C, Viswanath O, Kaye AD. A need for further education on buprenorphine in pain medicine. Health Psychol Res. 2023;11. https://doi.org/10.52965/001c.74958.

Speight C, Caiola C, Tyndall DE, Scott ES. Barriers and facilitators to nurse practitioner buprenorphine prescribing for opioid use disorder in primary care settings. J Am Assoc Nurse Pract. 2023;35(2):112–21. https://doi.org/10.1097/JXX.0000000000000811.

Article  PubMed  Google Scholar 

McAllister W. Drug Diplomacy in the Twentieth Century. 1999;1.

Acker C. Creating the American Junkie. 2006;1.

Jasinski DR. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry. 1978;35(4):501. https://doi.org/10.1001/archpsyc.1978.01770280111012.

Article  CAS  PubMed  Google Scholar 

Lewis JW. Buprenorphine. Drug Alcohol Depend. 1985;14(3–4):363–72. https://doi.org/10.1016/0376-8716(85)90067-5.

Article  CAS  PubMed  Google Scholar 

Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther. 1988;43(1):72–8. https://doi.org/10.1038/clpt.1988.13.

Article  CAS  PubMed  Google Scholar 

Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267(20):2750–5.

Article  CAS  PubMed  Google Scholar 

Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence. JAMA. 2010;304(14):1576. https://doi.org/10.1001/jama.2010.1427.

Article  CAS  PubMed  Google Scholar 

Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949–58. https://doi.org/10.1056/NEJMoa022164.

Article  CAS  PubMed  Google Scholar 

Bliley T. Drug Addiction Treatment Act of 2000 . https://www.congress.gov/bill/106th-congress/house-bill/2634.

FDA Approves First Generic Versions of Suboxone Sublingual Film, Which May Increase Access to Treatment for Opioid Dependence. United States Food and Drug Administration; 2018.

White J, Bell J, Saunders JB, et al. Open-label dose-finding trial of buprenorphine implants (Probuphine)® for treatment of heroin dependence. Drug Alcohol Depend. 2009;103(1–2):37–43. https://doi.org/10.1016/j.drugalcdep.2009.03.008.

Article  CAS  PubMed  Google Scholar 

Rosenthal RN, Lofwall MR, Kim S, Chen M, Beebe KL, Vocci FJ. Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine. JAMA. 2016;316(3):282. https://doi.org/10.1001/jama.2016.9382.

Article  CAS  PubMed  Google Scholar 

FDA Approves First Buprenorphine Implant for Treatment of Opioid Dependence. United States Food and Drug Administration; 2016.

Laffont CM, Gomeni R, Heidbreder C, Jones JP, Nasser AF. Population pharmacokinetic modeling after repeated administrations of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid use disorder. J Clin Pharmacol. 2016;56(7):806–15. https://doi.org/10.1002/jcph.665.

Article  CAS  PubMed  Google Scholar 

Haight BR, Learned SM, Laffont CM, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2019;393(10173):778–90. https://doi.org/10.1016/S0140-6736(18)32259-1.

Article  CAS  Google Scholar 

Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder. 2018.

Andorn AC, Haight BR, Shinde S, et al. Treating opioid use disorder with a monthly subcutaneous buprenorphine depot injection: 12-month safety, tolerability, and efficacy analysis. J Clin Psychopharmacol. 2020;40(3):231–9. https://doi.org/10.1097/JCP.0000000000001195.

Article  CAS  PubMed  PubMed Central  Google Scholar 

FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opioid use disorder. United States Food and Drug Administration. 2017.

Saltmer C. FDA Accepts Braeburn’s new drug application resubmission for BRIXADITM (buprenorphine) extended-release subcutaneous injection for moderate to severe opioid use disorder. Braeburn. December 8, 2022.

Karp JF, Butters MA, Begley AE, et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014;75(08):e785–93. https://doi.org/10.4088/JCP.13m08725.

Article  PubMed  PubMed Central  Google Scholar 

Khroyan TV, Wu J, Polgar WE, et al. BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice. Br J Pharmacol. 2015;172(2):668–80. https://doi.org/10.1111/bph.12796.

Article  CAS  PubMed  Google Scholar 

Kranzler HR, Lynch KG, Crist RC, et al. A delta-opioid receptor gene polymorphism moderates the therapeutic response to extended-release buprenorphine in opioid use disorder. Int J Neuropsychopharmacol. 2021;24(2):89–96. https://doi.org/10.1093/ijnp/pyaa069.

Article  CAS  PubMed  Google Scholar 

Zhuo GY, Chen MC, Lin TY, Lin ST, Chen DTL, Lee CWS. Opioid-modulated receptor localization and Erk1/2 phosphorylation in cells coexpressing μ-opioid and nociceptin receptors. Int J Mol Sci. 2023;24(2):1048. https://doi.org/10.3390/ijms24021048.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Aquino JP, Parida S, Sofuoglu M. The pharmacology of buprenorphine microinduction for opioid use disorder. Clin Drug Investig. 2021;41(5):425–36. https://doi.org/10.1007/s40261-021-01032-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khanna I, Pillarisetti S. Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain. J Pain Res. Published online December 2015:859. https://doi.org/10.2147/JPR.S85951.

Böger RH. Renal impairment: a challenge for opioid treatment? The role of buprenorphine Palliat Med. 2006;20(Suppl 1):s17-23.

Article  PubMed  Google Scholar 

Soyka M, Backmund M, Schmidt P, Apelt S. Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: results from a 12-month observational study. Am J Addict. 2014;23(6):563–9. https://doi.org/10.1111/j.1521-0391.2014.12131.x.

Article  PubMed  Google Scholar 

Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96(5):627–32. https://doi.org/10.1093/bja/ael051.

Article  CAS  PubMed  Google Scholar 

Spreen LA, Dittmar EN, Quirk KC, Smith MA. Buprenorphine initiation strategies for opioid use disorder and pain management: a systematic review. Pharmacotherapy J Human Pharmacol Drug Ther. 2022;42(5):411–427. https://doi.org/10.1002/phar.2676.

DeWire SM, Yamashita DS, Rominger DH, et al. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013;344(3):708–17. https://doi.org/10.1124/jpet.112.201616.

Article  CAS  PubMed  Google Scholar 

Mores KL, Cassell RJ, van Rijn RM. Arrestin recruitment and signaling by G protein-coupled receptor heteromers. Neuropharmacology. 2019;152:15–21. https://doi.org/10.1016/j.neuropharm.2018.11.010.

Article  CAS  PubMed  Google Scholar 

Mori T, Kuzumaki N, Arima T, et al. Usefulness for the combination of G protein- and β-arrestin-biased ligands of μ-opioid receptors: prevention of antinociceptive tolerance. Mol Pain. 2017;13:174480691774003. https://doi.org/10.1177/1744806917740030.

Article  CAS  Google Scholar 

Pedersen MF, Wróbel TM, Märcher-Rørsted E, et al. Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics. Neuropharmacology. 2020;166: 107718. https://doi.org/10.1016/j.neuropharm.2019.107718.

Article  CAS  PubMed  Google Scholar 

Infantino R, Mattia C, Locarini P, Pastore AL, Maione S, Luongo L. Buprenorphine: far beyond the “ceiling.” Biomolecules. 2021;11(6):816. https://doi.org/10.3390/biom11060816.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Navratilova E, Ji G, Phelps C, et al. Kappa opioid signaling in the central nucleus of the amygdala promotes disinhibition and aversiveness of chronic neuropathic pain. Pain. 2019;160(4):824–32. https://doi.org/10.1097/j.pain.0000000000001458.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med. 2019;13(2):93–103. https://doi.org/10.1097/ADM.0000000000000457.